BR112022002615A2 - Partículas virais e uso das mesmas para fabricar uma composição para tratar sinucleinopatias - Google Patents

Partículas virais e uso das mesmas para fabricar uma composição para tratar sinucleinopatias

Info

Publication number
BR112022002615A2
BR112022002615A2 BR112022002615A BR112022002615A BR112022002615A2 BR 112022002615 A2 BR112022002615 A2 BR 112022002615A2 BR 112022002615 A BR112022002615 A BR 112022002615A BR 112022002615 A BR112022002615 A BR 112022002615A BR 112022002615 A2 BR112022002615 A2 BR 112022002615A2
Authority
BR
Brazil
Prior art keywords
viral particles
manufacture
composition
synucleinopathies
treat
Prior art date
Application number
BR112022002615A
Other languages
English (en)
Portuguese (pt)
Inventor
Gonzalez Aseguinolaza Gloria
Luis Lanciego Perez José
Michael Linden Ralph
Original Assignee
Consorcio Centro De Investig Biomedica En Red
Fundacion Para La Investig Medica Aplicada
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67659024&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112022002615(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Consorcio Centro De Investig Biomedica En Red, Fundacion Para La Investig Medica Aplicada, UCB Biopharma SRL filed Critical Consorcio Centro De Investig Biomedica En Red
Publication of BR112022002615A2 publication Critical patent/BR112022002615A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01062—Glycosylceramidase (3.2.1.62)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
BR112022002615A 2019-08-12 2020-08-06 Partículas virais e uso das mesmas para fabricar uma composição para tratar sinucleinopatias BR112022002615A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19382706 2019-08-12
PCT/EP2020/072087 WO2021028299A1 (en) 2019-08-12 2020-08-06 Viral particles for use in treating synucleinopathies such as parkinson's diseases by gene therapy

Publications (1)

Publication Number Publication Date
BR112022002615A2 true BR112022002615A2 (pt) 2022-05-03

Family

ID=67659024

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022002615A BR112022002615A2 (pt) 2019-08-12 2020-08-06 Partículas virais e uso das mesmas para fabricar uma composição para tratar sinucleinopatias

Country Status (18)

Country Link
US (1) US20220298528A1 (https=)
EP (1) EP4013437A1 (https=)
JP (1) JP2023500011A (https=)
KR (1) KR20220099944A (https=)
CN (1) CN114786694A (https=)
AR (1) AR119609A1 (https=)
AU (1) AU2020328827A1 (https=)
BR (1) BR112022002615A2 (https=)
CA (1) CA3149844A1 (https=)
CL (1) CL2022000292A1 (https=)
CO (1) CO2022001192A2 (https=)
EC (1) ECSP22008949A (https=)
IL (1) IL290357A (https=)
MX (1) MX2022001676A (https=)
PE (1) PE20220601A1 (https=)
PH (1) PH12022550282A1 (https=)
TW (1) TW202120687A (https=)
WO (1) WO2021028299A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021015312A2 (pt) 2019-02-04 2021-11-09 Freeline Therapeutics Ltd Polinucleotídeos, partícula viral e composição
EP4192961A2 (en) * 2020-08-06 2023-06-14 Fundacion para la Investigacion Medica Aplicada Viral particles for use in treating tauopathies such as alzheimer's diseases by gene therapy
WO2023202637A1 (en) * 2022-04-19 2023-10-26 Shanghai Vitalgen Biopharma Co., Ltd. Recombinant aav vectors for treating neurodegenerative disorders
WO2024074142A1 (en) * 2022-10-08 2024-04-11 Lingyi Biotech Co., Ltd. Polynucleotides for the treatment of disease associated with gcase deficiency
WO2025063407A1 (ko) * 2023-09-22 2025-03-27 주식회사 스탠드업테라퓨티스 신규한 파킨슨 병 치료제

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3292206B8 (en) * 2015-05-07 2022-02-09 Takeda Pharmaceutical Company Limited Glucocerebrosidase gene therapy for parkinson's disease
EP3692075A4 (en) * 2017-10-03 2022-02-09 Prevail Therapeutics, Inc. GENE THERAPIES FOR LYSOSOMAL DISEASES
WO2019068854A1 (en) * 2017-10-06 2019-04-11 Ospedale San Raffaele S.R.L. GENE THERAPY OF NEURODEGENERATIVE DISEASES USING VAA VECTORS

Also Published As

Publication number Publication date
CN114786694A (zh) 2022-07-22
PE20220601A1 (es) 2022-04-25
AR119609A1 (es) 2021-12-29
ECSP22008949A (es) 2022-03-31
PH12022550282A1 (en) 2022-11-21
EP4013437A1 (en) 2022-06-22
TW202120687A (zh) 2021-06-01
JP2023500011A (ja) 2023-01-04
AU2020328827A1 (en) 2022-03-03
CL2022000292A1 (es) 2022-10-21
CO2022001192A2 (es) 2022-07-19
WO2021028299A1 (en) 2021-02-18
MX2022001676A (es) 2022-05-03
CA3149844A1 (en) 2021-02-18
US20220298528A1 (en) 2022-09-22
IL290357A (en) 2022-04-01
KR20220099944A (ko) 2022-07-14

Similar Documents

Publication Publication Date Title
BR112022002615A2 (pt) Partículas virais e uso das mesmas para fabricar uma composição para tratar sinucleinopatias
PH12019502793A1 (en) Aadc polynucleotides for the treatment of parkinson`s disease
MX2024000208A (es) Restos de administracion terapeutica novedosos y usos de estos.
BR112020017090A8 (pt) Imunoterapias relacionadas com microbioma
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
WO2019006418A3 (en) ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
MX2017016492A (es) Metodos para tratar tumores solidos usando terapia de combinacion de nanoparticula del inhibidor del objetivo mamifero de la rapamicina (mtor).
MX2017005834A (es) Polinucleotidos aad para el tratamiento de la enfermedad de parkinson.
BR112016015818A2 (pt) Compostos e respectivos usos para tratar pacientes com células cancerosas mutantes em relação a ros1
MX343706B (es) Derivados heterocíclicos novedosos.
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
EP4124346A3 (en) Compositions and methods for treating diseases
WO2019217397A3 (en) Compositions and methods for improving strand biased
MY184553A (en) Novel compounds as diacylglycerol acyltransferase inhibitors
MX2015006120A (es) Compuestos novedosos oralmente biodisponibles que modulan el control de la respiracion, y metodos de uso de los mismos.
EP4364805A3 (en) Novel pyridazines
WO2018083220A3 (en) Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines
EP4252755A3 (en) Therapeutic compounds
BR112022006530A2 (pt) Vetores virais adenoassociados para o tratamento da doença de niemann-pick tipo c
PH12014500250A1 (en) Substituted 3-(biphenyl-3-yl)-4 -hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one
BR112018017240A2 (pt) ?polinucleotídeo, vetor de ácido nucleico, preparação farmacêutica, kit, e, método para fabricar um vetor viral adenoassociado recombinante?
WO2020079489A3 (en) Treatment of neuropathy with igf-1-encoding dna constructs and hgf-encoding dna constructs
BR112018007768A2 (pt) composições e métodos para tratamento de homocistinúria
PH12021550903A1 (en) Novel pyridazines
WO2013012771A3 (en) Clinical applications of a recombinant human endostatin adenovirus (e10a) injection

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2845 DE 15-07-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.